| abstract |
The present invention treats IFN-γ mediated diseases by administering an antibody that interacts or binds to human interferon-gamma (IFN-γ), and a pharmaceutically effective amount of an antibody against IFN-γ. Providing a method for Also provided is a method of detecting the amount of IFN-γ in a sample using an antibody against IFN-γ. The present invention provides monoclonal antibodies that bind to interferon gamma (IFN-γ) and polynucleotides encoding them. This antibody can inhibit or modulate at least one of the biological activities of IFN-γ and can be useful to alleviate the effects of IFN-γ-mediated diseases. Hybridoma cells capable of producing the monoclonal antibodies of the invention and secreting them into the cell culture medium are also provided by the invention. The antibodies of the present invention may be useful for treating diseases mediated by IFN-γ. |